denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: MDS Foundation, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Bone Marrow Failure Syndromes, Diseases, Treatment Considerations, Myeloid Malignancies, Biological Processes
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Bone Marrow Failure Syndromes, Diseases, Treatment Considerations, Myeloid Malignancies, Biological Processes
Friday, December 6, 2024: 7:00 AM-10:00 AM
Grand Hall B
(Manchester Grand Hyatt San Diego)
Chairs:
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center
and
Casey L. O'Connell, MD, USC Keck School of Medicine, University of Southern California
Disclosures:
Mittelman: Abbvie: Research Funding; FibroGen: Other: Speaker; Novartis: Research Funding; BMS: Research Funding; Johnson & Johnson: Research Funding; Roche: Research Funding; CannaLean: Other: Shares; Dr. Reddy: Consultancy; BioConvergence: Consultancy. O'Connell: Sobi: Membership on an entity's Board of Directors or advisory committees.
Speakers:
Lionel Ades, MD, PhD, Université Paris Cité, APHP, Hôpital Saint-Louis
,
Rena Buckstein, MD, FRCPC, Sunnybrook Health Sciences Centre, University of Toronto
,
Aristoteles Giagounidis, MD, Marienhospital Düsseldorf
,
Jaroslaw Maciejewski, Taussig Cancer Institute, Cleveland Clinic Foundation
,
Ghulam Mufti, ARRAY(0xd875224)
,
Esther Natalie Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli
,
Magnus Tobiasson, MD, Karolinska Institutet
and
Lachelle D. Weeks, MD, PhD, Dana-Farber Cancer Institute
Disclosures:
Ades: Takeda: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; BMS: Honoraria, Research Funding. Buckstein: BMS: Honoraria, Research Funding; Abbvie: Honoraria; Taiho: Honoraria, Research Funding; Keros: Other: Advisory Board. Giagounidis: Amgen: Consultancy; BMS: Consultancy. Mufti: BMS/Celgene: Research Funding; Novartis: Research Funding. Oliva: Daiichi Sankyo: Consultancy, Honoraria; Grande Ospedale Metropolitano Bianchi Melacrino Morelli: Current Employment; Janssen: Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Alexion: Consultancy, Honoraria, Speakers Bureau; Bristol Myers Squibb: Consultancy, Honoraria, Speakers Bureau; Halia Therapeutics: Patents & Royalties; Amgen: Consultancy, Honoraria, Speakers Bureau; Sobi: Consultancy, Honoraria, Speakers Bureau; Ryvu: Consultancy, Honoraria, Patents & Royalties. Tobiasson: Pfizer: Honoraria. Weeks: Breakthrough Cancer Foundation: Research Funding; Edward P. Evans Foundation for MDS: Research Funding; ASH/Robert Wood Johnson Foundation AMFDP: Research Funding; Sobi: Consultancy; Abbvie: Consultancy.
The MDSF ASH 2024 Symposium will focus on challenges the MDS community faces in 2024. Progress has been made in understanding the biology, genetics and pathogenesis of MDS. Prognostication, and treatment strategies have been improved, but not satisfactorily. In 2024 we are still facing problems: Can we assess minimal residual disease ? We are still debating regarding the recommended Hb threshold for RBC transfusions. The increasing role of inflammation in the disease pathogenesis, raises the question of anti-inflammatory treatment. The reports on germline mutations and their role in MDS in adulthood might change our genetic screening policy. Finally, we are still puzzled whether patients with higher-risk disease should be treated with hypomethylating agents only, as the only proven treatment, or additional therapy might improve the outcome. The symposium will highlight these challenges, and based on recent advances in the field, potential solutions will be presented and discussed.
See more of: Friday Satellite Symposia